Incidence of antiplatelet factor 4/heparin antibody induction in patients undergoing percutaneous coronary revascularization

Tyler J. Gluckman; Jodi B. Segal; Natalie L. Fredde; Kenneth E. Saland; Jayesh T. Jani; Jeanine M. Walenga; M. Margaret Prechel; Kathleen M. Citro; David A. Zidar; Emily Fox; Steven P. Schulman; Thomas S. Kickler; Jeffrey J. Rade

doi:10.1016/j.amjcard.2004.11.026

Incidence of antiplatelet factor 4/heparin antibody induction in patients undergoing percutaneous coronary revascularization

Tyler J. Gluckman, Jodi B. Segal, Natalie L. Fredde, Kenneth E. Saland, Jayesh T. Jani, Jeanine M. Walenga, M. Margaret Prechel, Kathleen M. Citro, David A. Zidar, Emily Fox, Steven P. Schulman, Thomas S. Kickler, Jeffrey J. Rade

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

The incidence of antiplatelet factor-4/heparin antibody formation in patients who receive contemporary doses of unfractionated heparin in the setting of percutaneous coronary revascularization is unknown. Also unknown is the ability of these antibodies to activate platelets or adversely affect clinical outcome in the absence of clinically recognized heparin-induced thrombocytopenia. To address these questions, we serially measured antiplatelet factor-4/heparin antibody levels and performed serotonin release assays in patients who underwent percutaneous coronary intervention. Correlations were then made across antibody induction, heparin exposure, and clinical outcome at 6 months.

Original language	English (US)
Pages (from-to)	744-747
Number of pages	4
Journal	American Journal of Cardiology
Volume	95
Issue number	6
DOIs	https://doi.org/10.1016/j.amjcard.2004.11.026
State	Published - Mar 15 2005
Externally published	Yes

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.amjcard.2004.11.026

Cite this

Gluckman, T. J., Segal, J. B., Fredde, N. L., Saland, K. E., Jani, J. T., Walenga, J. M., Prechel, M. M., Citro, K. M., Zidar, D. A., Fox, E., Schulman, S. P., Kickler, T. S., & Rade, J. J. (2005). Incidence of antiplatelet factor 4/heparin antibody induction in patients undergoing percutaneous coronary revascularization. American Journal of Cardiology, 95(6), 744-747. https://doi.org/10.1016/j.amjcard.2004.11.026

Gluckman, TJ, Segal, JB, Fredde, NL, Saland, KE, Jani, JT, Walenga, JM, Prechel, MM, Citro, KM, Zidar, DA, Fox, E, Schulman, SP , Kickler, TS & Rade, JJ 2005, 'Incidence of antiplatelet factor 4/heparin antibody induction in patients undergoing percutaneous coronary revascularization', American Journal of Cardiology, vol. 95, no. 6, pp. 744-747. https://doi.org/10.1016/j.amjcard.2004.11.026

@article{d71ddc848ff748c6bec7c46ceee54222,

title = "Incidence of antiplatelet factor 4/heparin antibody induction in patients undergoing percutaneous coronary revascularization",

abstract = "The incidence of antiplatelet factor-4/heparin antibody formation in patients who receive contemporary doses of unfractionated heparin in the setting of percutaneous coronary revascularization is unknown. Also unknown is the ability of these antibodies to activate platelets or adversely affect clinical outcome in the absence of clinically recognized heparin-induced thrombocytopenia. To address these questions, we serially measured antiplatelet factor-4/heparin antibody levels and performed serotonin release assays in patients who underwent percutaneous coronary intervention. Correlations were then made across antibody induction, heparin exposure, and clinical outcome at 6 months.",

author = "Gluckman, {Tyler J.} and Segal, {Jodi B.} and Fredde, {Natalie L.} and Saland, {Kenneth E.} and Jani, {Jayesh T.} and Walenga, {Jeanine M.} and Prechel, {M. Margaret} and Citro, {Kathleen M.} and Zidar, {David A.} and Emily Fox and Schulman, {Steven P.} and Kickler, {Thomas S.} and Rade, {Jeffrey J.}",

year = "2005",

month = mar,

day = "15",

doi = "10.1016/j.amjcard.2004.11.026",

language = "English (US)",

volume = "95",

pages = "744--747",

journal = "American Journal of Cardiology",

issn = "0002-9149",

publisher = "Elsevier Inc.",

number = "6",

}

TY - JOUR

T1 - Incidence of antiplatelet factor 4/heparin antibody induction in patients undergoing percutaneous coronary revascularization

AU - Gluckman, Tyler J.

AU - Segal, Jodi B.

AU - Fredde, Natalie L.

AU - Saland, Kenneth E.

AU - Jani, Jayesh T.

AU - Walenga, Jeanine M.

AU - Prechel, M. Margaret

AU - Citro, Kathleen M.

AU - Zidar, David A.

AU - Fox, Emily

AU - Schulman, Steven P.

AU - Kickler, Thomas S.

AU - Rade, Jeffrey J.

PY - 2005/3/15

Y1 - 2005/3/15

N2 - The incidence of antiplatelet factor-4/heparin antibody formation in patients who receive contemporary doses of unfractionated heparin in the setting of percutaneous coronary revascularization is unknown. Also unknown is the ability of these antibodies to activate platelets or adversely affect clinical outcome in the absence of clinically recognized heparin-induced thrombocytopenia. To address these questions, we serially measured antiplatelet factor-4/heparin antibody levels and performed serotonin release assays in patients who underwent percutaneous coronary intervention. Correlations were then made across antibody induction, heparin exposure, and clinical outcome at 6 months.

AB - The incidence of antiplatelet factor-4/heparin antibody formation in patients who receive contemporary doses of unfractionated heparin in the setting of percutaneous coronary revascularization is unknown. Also unknown is the ability of these antibodies to activate platelets or adversely affect clinical outcome in the absence of clinically recognized heparin-induced thrombocytopenia. To address these questions, we serially measured antiplatelet factor-4/heparin antibody levels and performed serotonin release assays in patients who underwent percutaneous coronary intervention. Correlations were then made across antibody induction, heparin exposure, and clinical outcome at 6 months.

UR - http://www.scopus.com/inward/record.url?scp=20044372522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20044372522&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2004.11.026

DO - 10.1016/j.amjcard.2004.11.026

M3 - Article

C2 - 15757601

AN - SCOPUS:20044372522

SN - 0002-9149

VL - 95

SP - 744

EP - 747

JO - American Journal of Cardiology

JF - American Journal of Cardiology

IS - 6

ER -

Incidence of antiplatelet factor 4/heparin antibody induction in patients undergoing percutaneous coronary revascularization

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this